Influence of pegylation and hapten location at the surface of radiolabelled liposomes on tumour immunotargeting using bispecific antibody

Nuclear Medicine and Biology

Volumn 41, Issue S, 2014, Pages

  Rauscher, A ^a   Frindel, M ^a   Maurel, C ^a   Maillasson, M ^a,b   Le Saec P ^a   Rajerison, H ^a   Gestin, J F ^a   Barbet, J ^a   Faivre Chauvet, A ^a   Mougin Degraef, M ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Biacore; Bispecific Antibody; Pegylated Liposomes; Pretargeting; Radioimmunotherapy

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENE GLYCOL) 1000]PENTETATE INDIUM HAPTEN IN 111; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENE GLYCOL) 2000]PENTETATE INDIUM HAPTEN IN 111; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE PENTETATE INDIUM HAPTEN IN 111; BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; HAPTEN; INDIUM 111; IODINE 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENE GLYCOL) 1000]PENTETATE INDIUM HAPTEN I 125; IODINE 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENE GLYCOL) 2000]PENTETATE INDIUM HAPTEN I 125; IODINE 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE PENTETATE INDIUM HAPTEN I 125; IODINE 125; LIPOSOME; PENTETATE INDIUM ANTIBODY; PENTETATE INDIUM HAPTEN; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CHEMICAL MODIFICATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IMMOBILIZATION; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; ISOTOPE LABELING; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PEGYLATION; PROCESS OPTIMIZATION; RADIATION DOSE; RADIOACTIVITY; RADIOIMMUNOTHERAPY; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; TUMOR IMMUNOTARGETING; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; CELL MEMBRANE; CHEMISTRY; COLORECTAL NEOPLASMS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, BISPECIFIC; CELL LINE, TUMOR; CELL MEMBRANE; COLORECTAL NEOPLASMS; FEMALE; HAPTENS; HUMANS; LIPOSOMES; MICE; POLYETHYLENE GLYCOLS; RADIOIMMUNOTHERAPY;

EID: 84899123026     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.12.012     Document Type: Article

References (26)

1. Barbet J., Bardiès M., Bourgeois M., Chatal J.-F., Chérel M., Davodeau F., et al. Radiolabeled antibodies for cancer imaging and therapy. Methods Mol Biol 2012, 907:681-697.
2. Ferrer L., Rauscher A., Barbet J., Kraeber-Bodéré F. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Front Oncol 2013, 3:177.
3. DeNardo S.J., Denardo G.L. Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys 2006, 66(2 Suppl):S89-S95.
4. Sharkey R.M., Goldenberg D.M. Cancer radioimmunotherapy. Immunotherapy 2011, 3(3):349-370. [mars].
5. Barbet J., Kraeber-Bodéré F., Vuillez J.P., Gautherot E., Rouvier E., Chatal J.F. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm 1999, 14(3):153-166. [juin].
6. Chatal J.-F., Campion L., Kraeber-Bodéré F., Bardet S., Vuillez J.-P., Charbonnel B., et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006, 24(11):1705-1711. [10 avr].
7. Frampas E., Maurel C., Remaud-Le Saëc P., Mauxion T., Faivre-Chauvet A., Davodeau F., et al. Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. Eur J Nucl Med Mol Imaging 2011, 38(12):2153-2164.
8. Elizondo E., Moreno E., Cabrera I., Córdoba A., Sala S., Veciana J., et al. Liposomes and other vesicular systems: structural characteristics, methods of preparation, and use in nanomedicine. Prog Mol Biol Transl Sci 2011, 104:1-52.
9. Chang H.-I., Yeh M.-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012, 7:49-60.
10. Phillips W.T., Goins B.A., Bao A. Radioactive liposomes. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1(1):69-83.
11. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990, 268(1):235-237. [30 juill].
12. Milla P., Dosio F., Cattel L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab 2012, 13(1):105-119. [janv].
13. Botosoa E.P., Maillasson M., Mougin-Degraef M., Remaud-Le Saëc P., Gestin J.-F., Jacques Y., et al. Antibody-Hapten Recognition at the Surface of Functionalized Liposomes Studied by SPR: Steric Hindrance of Pegylated Phospholipids in Stealth Liposomes Prepared for Targeted Radionuclide Delivery. J Drug Deliv 2011, 1-9.
14. Vemuri S., Rhodes C. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv 1995, 70(2):95-111. [juill].
15. Mougin-Degraef M., Bourdeau C., Jestin E., Saï-Maurel C., Bourgeois M., Saëc P.R.-L., et al. Doubly radiolabeled liposomes for pretargeted radioimmunotherapy. Int J Pharm nov 1 2007, 344(1-2):110-117.
16. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965, 13(1):238-252. [aoÛt].
17. Mougin-Degraef M., Jestin E., Bruel D., Remaud-Le Saëc P., Morandeau L., Faivre-Chauvet A., et al. High-activity radio-iodine labeling of conventional and stealth liposomes. J Liposome Res 2006, 16(1):91-102.
18. Bolton A.E., Hunter W.M. The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Application to the radioimmunoassay. Biochem J 1973, 133(3):529-539. [juill].
19. Wu M.S., Robbins J.C., Bugianesi R.L., Ponpipom M.M., Shen T.Y. Modified in vivo behavior of liposomes containing synthetic glycolipids. Biochim Biophys Acta 1981, 674(1):19-29. 17 avr.
20. Anderluh G., Besenicar M., Kladnik A., Lakey J.H., Macek P. Properties of nonfused liposomes immobilized on an L1 Biacore chip and their permeabilization by a eukaryotic pore-forming toxin. Anal Biochem Sept 1 2005, 344(1):43-52.
21. Lehtinen J., Magarkar A., Stepniewski M., Hakola S., Bergman M., Róg T., et al. Analysis of cause of failure of new targeting peptide in PEGylated liposome: Molecular modeling as rational design tool for nanomedicine. Eur J Pharm Sci 2012, 46(3):121-130. 14 juin.
22. Cao Y., Suresh M.R. Bispecific MAb aided liposomal drug delivery. J Drug Target 2000, 8(4):257-266.
23. Xiao Z., McQuarrie S.A., Suresh M.R., Mercer J.R., Gupta S., Miller G.G. A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro. J Biotechnol Mars 28 2002, 94(2):171-184.
24. Zavaleta C.L., Phillips W.T., Soundararajan A., Goins B.A. Use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model 2007, 337(1-2):316-328. [7 juin].
25. Lehtinen J., Raki M., Bergström K.A., Uutela P., Lehtinen K., Hiltunen A., et al. Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma. PLoS ONE 2012, 7(7):e41410.
26. Sofou S., Sgouros G. Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin Drug Deliv 2008, 5(2):189-204. [févr].